commercialization agreement
Personalis believes the move will get its minimal residual disease test into the hands of doctors more quickly while it continues to validate additional indications.
Mainz Biomed, Fugene Genetics Partner on Colorectal Cancer Test Launch in Israel
The deal is one of several struck this year by Mainz Biomed for the marketing of its stool sample-based ColoAlert molecular test for colorectal cancer.
Mainz Biomed Inks Commercialization Deals for Colorectal Cancer Test in UK, Spain
The test combines analysis of DNA, mRNA, and fecal immunohistochemistry to identify cancer in asymptomatic individuals from a stool sample.
Unilabs, Ambry Genetics Partner to Market Research-Use Genomic Testing Services Internationally
The companies aim to offer genetic testing for biopharma and government-sponsored research in Europe, Latin America, and the Middle East.
Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment
Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.
Oct 12, 2021